Abstract
Treatment of sporadic cardiac myxoma (CM) has always been a challenging task. Currently, surgical excision remains the only option; however, targeted drug discovery schemes are in progress in order to improve treatment strategies and efficacy. The molecular mechanisms behind CM pathogenesis are still not totally unveiled thus drug target identification is still at early steps, trying to compile structured data on the pathophysiology of CM, targets and targeting moieties. Five critical disease pathways involving molecules of seven functional groups have been recently shown by us to be associated with the pathogenesis of CM. In addition, 15 to 20 drug targets and their targeting molecules have also mapped on pathways in an effort to start decoding the molecular profiles based on which early efforts for CM patient stratification into targeted therapeutic regimes. The present review describes the current data and discusses critical issues in the field of targeted and personalized medicine of CM.
Keywords: Critical disease pathways, cardiac myxoma markers, drug targets, targeted therapy
Current Cancer Drug Targets
Title: Molecular Features, Markers, Drug Targets, and Prospective Targeted Therapeutics in Cardiac Myxoma
Volume: 9 Issue: 6
Author(s): Debmalya Barh, Anil Kumar, Suvro Chatterjee and Triantafillos Liloglou
Affiliation:
Keywords: Critical disease pathways, cardiac myxoma markers, drug targets, targeted therapy
Abstract: Treatment of sporadic cardiac myxoma (CM) has always been a challenging task. Currently, surgical excision remains the only option; however, targeted drug discovery schemes are in progress in order to improve treatment strategies and efficacy. The molecular mechanisms behind CM pathogenesis are still not totally unveiled thus drug target identification is still at early steps, trying to compile structured data on the pathophysiology of CM, targets and targeting moieties. Five critical disease pathways involving molecules of seven functional groups have been recently shown by us to be associated with the pathogenesis of CM. In addition, 15 to 20 drug targets and their targeting molecules have also mapped on pathways in an effort to start decoding the molecular profiles based on which early efforts for CM patient stratification into targeted therapeutic regimes. The present review describes the current data and discusses critical issues in the field of targeted and personalized medicine of CM.
Export Options
About this article
Cite this article as:
Barh Debmalya, Kumar Anil, Chatterjee Suvro and Liloglou Triantafillos, Molecular Features, Markers, Drug Targets, and Prospective Targeted Therapeutics in Cardiac Myxoma, Current Cancer Drug Targets 2009; 9 (6) . https://dx.doi.org/10.2174/156800909789271549
DOI https://dx.doi.org/10.2174/156800909789271549 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Combined Modality Treatment for Locally Advanced Pancreatic Cancer
Current Cancer Therapy Reviews A Novel Combined Pharmacophore Mapping and Quantitative Structure Selectivity Relationship Analysis for the Development of Potent and Selective Human Aldose Reductase Inhibitors
Current Computer-Aided Drug Design Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways
Current Neuropharmacology Technetium Labeled Small Peptide Radiopharmaceuticals in the Identification of Lung Cancer
Current Pharmaceutical Design Low-Density Lipoprotein Cholesterol (LDL-C): How Low?
Current Vascular Pharmacology Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Current Medicinal Chemistry Post-locoregional Therapy MRI Evaluation of Malignant Liver Lesions
Current Cancer Therapy Reviews Synthesis and Chymotrypsin Inhibitory Activity of Substituted Oxazolones
Letters in Drug Design & Discovery Theranostics Based on Iron Oxide and Gold Nanoparticles for Imaging- Guided Photothermal and Photodynamic Therapy of Cancer
Current Topics in Medicinal Chemistry High Cytotoxicity and Apoptotic Effects of Natural Bioactive Benzofuran Derivative on the MCF-7 Breast Cancer Cell Line
Combinatorial Chemistry & High Throughput Screening Tribulus arabicus and Tribulus macropterus are Comparable to Tribulus terrestris: An Antioxidant Assessment
Current Bioactive Compounds Labeling Strategies with F-18 for Positron Emission Tomography Imaging
Medicinal Chemistry Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets An Update on Potential Molecular Mechanisms Underlying the Actions of Snake Venom L-amino Acid Oxidases (LAAOs)
Current Medicinal Chemistry The Novel Synthesized Pyridazinone Derivates had the Antiproliferative and Apoptotic Effects in SHSY5Y and HEP3B Cancer Cell Line
Letters in Organic Chemistry Editorial [Hot Topic: Anti-Cancer Drugs (Executive Editor: Elke S. Bergmann-Leitner)]
Current Pharmaceutical Design Preface
Current Drug Targets Ascorbic Acid: An Old Player with a Broad Impact on Body Physiology Including Oxidative Stress Suppression and Immunomodulation: A Review
Mini-Reviews in Medicinal Chemistry